Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2018
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2018
SUMMARY
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 6 molecules. The latest report Adrenocorticotropic Hormone Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Genetic Disorders and Musculoskeletal Disorders which include indications Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease), Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Gouty Arthritis (Gout) and Multiple Sclerosis.
Furthermore, this report also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 6 molecules. The latest report Adrenocorticotropic Hormone Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Genetic Disorders and Musculoskeletal Disorders which include indications Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease), Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Gouty Arthritis (Gout) and Multiple Sclerosis.
Furthermore, this report also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
- The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development
Crinetics Pharmaceuticals Inc
Ipsen SA
MallInckrodt Plc
Novartis AG
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23B065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cosyntropin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones
Featured News & Press Releases
Aug 06, 2018: Mallinckrodt enrolls first patient in Phase ll trial of MNK-1411
Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies
Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)
Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel
May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel
Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert
Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting
Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)
Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development
Crinetics Pharmaceuticals Inc
Ipsen SA
MallInckrodt Plc
Novartis AG
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23B065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cosyntropin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones
Featured News & Press Releases
Aug 06, 2018: Mallinckrodt enrolls first patient in Phase ll trial of MNK-1411
Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies
Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)
Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel
May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel
Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert
Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting
Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)
Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Crinetics Pharmaceuticals Inc, H2 2018
Pipeline by Ipsen SA, H2 2018
Pipeline by MallInckrodt Plc, H2 2018
Pipeline by Novartis AG, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Crinetics Pharmaceuticals Inc, H2 2018
Pipeline by Ipsen SA, H2 2018
Pipeline by MallInckrodt Plc, H2 2018
Pipeline by Novartis AG, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Crinetics Pharmaceuticals Inc
Ipsen SA
MallInckrodt Plc
Novartis AG
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Crinetics Pharmaceuticals Inc
Ipsen SA
MallInckrodt Plc
Novartis AG
